12.03.19
In the United States, we are engaged in the challenging but important conversation about how to assess the value of pharmaceuticals. While efforts to improve the frameworks for drug value assessment are emerging, we are missing an important opportunity if we continue to focus all value assessment energy on just drugs. To be truly relevant to sustainable value-based health care decision-making, we must advance methods and tools that can effectively support comparative assessment of a broader array…
